Leveraging on its large state-of-the-art manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, Aurobindo Pharma is targeting to achieve $2 billion turnover during the current financial year. The city-based drug maker is also hoping to seek approvals for nine more injectables from US FDA.
The consolidated revenue (net) from operations was higher over the previous year by 38.3% at nearly Rs 8,100 crore ($1.4 billon at Rs 58 per dollar) during 2013-14 as against Rs 5,855 crore in the previous year.
The company has achieved a remarkable milestone of 300 submissions to the US FDA at the end of 2013 and as at end of March 2014 the submissions totaled 336 ANDA filings.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
No comments:
Post a Comment